Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM
View Full Paper
Ask AI
Bookmark
Share
Key Points
To assess the functional fitness of CAR-T cells in bone marrow and its correlation with prolonged progression-free survival in RRMM patients receiving anti-BCMA therapy.
Conducted a phase 1 clinical trial with 55 RRMM patients treated with PHE885 CAR-T cell therapy.
Performed immune-monitoring evaluations of CAR-T cell activation and functionality in bone marrow using CyTOF analysis.
Compared CAR-T cell characteristics between patients achieving sustained complete response (sCR) and those who progressed.
Assessed regulatory T cell populations and various activation markers on CAR-T cells.
Overall response rate was found to be 98%, with a complete response rate of 55%.
Significant differences in regulatory T cell populations were observed between patients with sCR and those with disease progression.
sCR patients exhibited higher expression of activation markers (CD38, CD28, CD27) and cytokines (IL-2, granzyme-B) compared to PD patients, suggesting enhanced anti-tumor activity.
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Phase 1 trial demonstrates improved T-cell activation and anti-tumor activity in RRMM patients, indicating potential for prolonged responses.